Drugs / Rifampin
Rifampin
DrugRifampin is a rifamycin-class antibacterial used primarily in tuberculosis treatment and meningococcal carrier eradication. It is a semisynthetic rifamycin derivative whose antimicrobial activity includes inhibition of mycobacterial DNA-dependent RNA polymerase. U.S. brand Rifadin capsules were initially approved in 1971.
- Trials
- 450
- Recruiting
- 32
- Completed
- 320
- With results
- 91
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 2 | 1 | — | — | 1 | 4 |
| Phase 1 | 6 | 9 | — | 2 | 206 | 7 | 6 | 1 | 17 | 254 |
| Phase 1/2 | — | — | — | — | 6 | — | — | — | — | 6 |
| Phase 2 | 7 | 6 | — | 2 | 33 | 6 | — | 1 | 3 | 58 |
| Phase 2/3 | 1 | — | — | 1 | 7 | — | — | — | — | 9 |
| Phase 3 | 10 | 5 | — | 2 | 21 | 1 | 1 | — | 4 | 44 |
| Phase 4 | 5 | 1 | 1 | — | 22 | 3 | 1 | — | 9 | 42 |
| Not applicable | 2 | 1 | 1 | — | 20 | 1 | — | — | 3 | 28 |
| Unknown | 1 | — | — | — | 3 | 1 | — | — | — | 5 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | — | 17 | 2 | 24 | 3 | 18 | 10 | 7 | 2 | 83 |
| Tuberculosis, Pulmonary | — | 1 | 1 | 27 | 4 | 12 | 2 | 4 | 2 | 53 |
| HIV Infections | — | 2 | — | 4 | 1 | 4 | 4 | 6 | 1 | 22 |
| Latent Tuberculosis | — | 3 | — | 1 | 2 | 4 | 4 | — | — | 14 |
| Acquired Immunodeficiency Syndrome | — | 2 | — | 1 | 1 | 2 | 2 | 5 | — | 13 |
| Neoplasms | — | 13 | — | — | — | — | — | — | — | 13 |
| Lymphoma | — | 8 | — | — | — | — | — | — | — | 8 |
| Lymphoma, Non-Hodgkin | — | 7 | — | — | — | — | — | — | — | 7 |
| Tuberculosis, Meningeal | — | — | 1 | 4 | 1 | 1 | — | — | — | 7 |
| Cystic Fibrosis | — | 2 | — | 2 | — | — | 1 | 1 | — | 6 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 4 |
| 2 | Boehringer Ingelheim | 11 | 0 |
| 3 | Pfizer | 11 | 0 |
| 4 | Bristol-Myers Squibb | 10 | 0 |
| 5 | AstraZeneca | 9 | 0 |
| 6 | Johns Hopkins University | 9 | 1 |
| 7 | Celgene | 8 | 0 |
| 8 | Jiangsu HengRui Medicine Co., Ltd. | 8 | 0 |
| 9 | Centers for Disease Control and Prevention | 7 | 3 |
| 10 | Millennium Pharmaceuticals, Inc. | 7 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Rifampin | 450 |
| 2 | Isoniazid | 97 |
| 3 | Itraconazole | 88 |
| 4 | Pyrazinamide | 77 |
| 5 | Ethambutol | 76 |
| 6 | Moxifloxacin | 30 |
| 7 | Midazolam | 24 |
| 8 | Levofloxacin | 21 |
| 9 | bedaquiline | 20 |
| 10 | rifapentine | 19 |
Evidence
- Results reported
- 28.4%91 of 320 completed
- Published
- 8.4%27 of 320 completed
- Primary endpoint met
- 25.3%49 of 194 analyses
- Median months to report
- 16
Documents disclosed
Trial profile
- Median enrollment
- 40
- Median duration
- 11.3months
- Countries
- 70
- Study sites
- 1489
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 36
- Phase 1
- 27
- Phase 1/2
- 35
- Phase 2
- 112
- Phase 2/3
- 455
- Phase 3
- 383
- Phase 4
- 125
- Not applicable
- 67
- Unknown
- 550
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Cape Town | South Africa | 30 |
| 2 | Kampala | Uganda | 23 |
| 3 | Dallas | United States | 20 |
| 4 | Shanghai | China | 17 |
| 5 | Baltimore | United States | 16 |
| 6 | New York | United States | 15 |
| 7 | Beijing | China | 14 |
| 8 | Durban | South Africa | 14 |
| 9 | Johannesburg | South Africa | 14 |
| 10 | Nashville | United States | 14 |
Terminations
- Terminated
- 20
- Withdrawn
- 8
- Suspended
- 2
- Stopped for recruitment
- 0.4%2 of 450 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04694586 Suspended | Suspended | Suspended 15th of Nov 2023 due to conditions affecting recruitment process. | 2030-05-31 |
| NCT07242781 Terminated | Terminated | Business objectives have changed | 2026-04-21 |
| NCT06191692 Withdrawn | Withdrawn | Lack of Rifapentine | 2025-12-30 |
| NCT04311502 Terminated | Terminated | Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks. | 2025-06-24 |
| NCT05977868 Terminated | Terminated | DSMB recommendation based on safety benefit in Experimental (oral) arm | 2025-02-14 |
| NCT05971602 Terminated | Terminated | Data generated in the Gates MRI-TBD06-201 trial do not support the investigational regimens being able to achieve the trial objective of identifying a new regimen to treat tuberculosis in 3 months or less. | 2025-02-06 |
| NCT05156437 Terminated | Terminated | The study was stopped because all five participants were lost to follow-up before completing treatment or any assessments, leaving no outcome data available and making continuation of the trial infeasible. | 2024-10-31 |
| NCT02875223 Terminated | Terminated | Business objectives have changed | 2024-03-25 |
| NCT04959266 Terminated | Terminated | The study terminated because the clinical development programme for Adavosertib has been discontinued | 2022-06-01 |
| NCT02547116 Withdrawn | Withdrawn | Administrative delay | 2021-12-31 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: